Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

$(2,911) $(1,102) $(4,013)

Basic and diluted

net loss per

share $(0.31) $(0.04) $(0.35) $(0.19) $(0.07) $(0.26)

Research and

development

expenses $8,870 $367 $9,237 $9,975 $549 $10,524

General and

administrative

expenses $1,768 $495 $2,263 $1,573 $553 $2,126

Six Months Ended Six Months Ended

June 30, 2008 (1) June 30, 2007 (1)

Stock- Stock-

based Reported based Reported

compensation GAAP compensation GAAP

non-GAAP expense results non-GAAP expense results

Net loss $(1,992) $(1,488) $(3,480) $(3,020) $(2,091) $(5,111)

Basic and diluted

net loss per

share $(0.10) $(0.07) $(0.17) $(0.20) $(0.14) $(0.33)

Research and

development

expenses $19,925 $661 $20,586 $19,492 $1,050 $20,542

General and

administrative

expenses $3,557 $827 $4,384 $3,318 $1,041 $4,359

SGX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

June 30, December 31,

2008 2007

Assets

Cash, cash equivalents and short-term investments $23,676 $38,990

Accounts receivable 954 2,706

Other current assets 1,217 1,187

Property and equipment, net 3,5
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 2015 Veolia’s environmental monitoring technology ... American distribution agreement with VWR to distribute TECTA™ ... more than 160 years of experience, VWR, a ... laboratory and production facilities, has cultivated a value ... services to enable science. Endetec’s TECTA™ B16, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... -- Health eCareers, the healthcare industry,s online career hub, ... looking for the flexibility of short-term assignments through ... tool dedicated exclusively to temporary and shift work ... employers to quickly find and hire experienced professionals ... other temporary positions, eliminating the time and resources ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... Using two abundant and relatively inexpensive elements, ... webbing of nano-scale wires that multiplies surface area ... in electronics and energy applications. , , Researchers grew ... network of branches that resemble flat, rectangular netting, ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced that ... vice president and chief medical officer. Dr.,Houghton will ... brings to Anesiva deep commercial and product development,expertise ... in,anesthesiology," said Mr. Kranda. "He fills a key ...
... Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee of ... of creditors, announced today that all pharmaceutical,intellectual property ... on October 10,2008., With SRx-503, Spherics has ... line treatment for Parkinson,s disease. Current global sales ...
Cached Biology Technology:Scientists grow 'nanonets' able to snare added energy transfer 2Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer 2Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery 2
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... world,s electronic waste is being shipped to China for ... there to recover usable materials from computers, cell phones, ... and environmental hazards. Scientists from China and the ... emissions from an e-waste recycling workshop in southern China, ...
... Research from the University of Exeter has revealed taking ... can significantly boost stamina during high-intensity exercise. The study ... the supplement can allow people to exercise up to 20% ... This comes on the back of previous research from ...
... RENO, Nev. There is still much that ... of Nevada, Reno psychologist has added to the body ... to try to demystify, prevent and treat the mysterious ... Jeffrey Hutsler, assistant professor of psychology at the University ...
Cached Biology News:Scientists concerned about environmental impact of recycling of e-waste 2Supplement produces a 'striking' endurance boost 2University of Nevada professor studies structural basis for autism disorders 2
... vacuum concentrators/centrifugal evaporators offers a wide range ... and safe concentration of heat-labile samples. The ... or high vacuum pumps, a choice of ... rotors (eliminating sample loss by transfer), ensuring ...
... George Paxinos Affiliation: School of Psychology, The ... Watson Affiliation: Curtin University of Technology, Perth, Australia ... atlas of the rat brain. It is ... mm) revison and extension of the compact 3rd ...
... MBS Start up kit. Includes configured Laptop ... of 1 MultiBlock satellite thermal Cycler ... User friendly software. Store/track run ... heated lid. Outstanding uniformity. Advanced ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: